Elsalys Biotech has entered a preclinical collaboration with German cancer research institute DKFZ to initiate the development of ELB021 in B-Cell leukaemia, under European Union (EU) sponsored programme Eurostars.

ELB021 is the company’s first-in-class monoclonal antibody that targets the cell-surface receptor CD160.

The CD160 receptor helps control both the innate and adaptive immune response and neo-angiogenesis regulation.

It is also a tumour-antigen that can mediate activation of several cancer cells, notably in B-cell leukaemia such as Chronic Lymphoid (CLL) and Hairy-Cell Leukaemias (HCL).

In-licensed by the company from Inserm Transfert in February last year, ELB021 is a new immunotherapy antibody that combines complementary mechanisms of action to improve the efficacy / toxicity cancer treatment ratio, particularly in B-cell leukaemia.

Elsalys Biotech co-founder and chief executive officer Dr Christine Guillen said: “The recognition by the Eurostars programme underlies the therapeutic potential of our two-in-one approach in oncology.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
"The recognition by the Eurostars programme underlies the therapeutic potential of our two-in-one approach in oncology."

“This new funding accelerates the development of this proprietary first-in-class antibody. We are also very proud to further collaborate with the DKFZ, a European leader in cancer research.”

Early studies have demonstrated that ELB021 helps stimulate innate and adaptive anti-tumour immune response and eliminates selective cancer cells expressing CD160.

The overall budget amount for the preclinical collaboration is valued at €1m.

Based on the preliminary data of ELB021, the main aim is to generate the preclinical proof-of-concept and the pharmacological package that open the way to the first-in-human trial.

DKFZ will help measure CD160 expression in CLL cells on large patients' cohort and assess the efficacy and safety of the anti-CD160 antibody in relevant mouse models.

Clinical trials with anti-CD160 are expected to be initiated by 2019 (in ophtalmology) and 2020 (in oncology).